First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).

Johann S. de Bono,Natalie Cook,Evan Y. Yu,P. N. Lara,Judy S. Wang,Yoshihiko Yamasaki,Ikuo Yamamiya,Ping Gao,Elizabeth Martine Calleja,Dana E. Rathkopf

First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).

2021

Johann S. de Bono
Natalie Cook
Evan Y. Yu
P. N. Lara
Judy S. Wang
Yoshihiko Yamasaki
Ikuo Yamamiya
Ping Gao
Elizabeth Martine Calleja
Dana E. Rathkopf

5031Background: Second-generation AR signaling inhibitors have improved outcomes from mCRPC; drug resistance, however, invariably evolves with AR overexpression, AR mutation, or AR-SVs and continue...

Keywords:

Medicine
Drug resistance
Chemotherapy
Androgen receptor
Downregulation and upregulation
Prostate cancer
Cancer research
Refractory
Enzalutamide
Antagonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations